Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of panitumumab plus paclitaxel as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma
2010-018898-37Phase 2Completed
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- Start
- Apr 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab and paclitaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello. Primary endpoint: Objective response rate. Started Apr 2010; status: completed.
02
Drugs
panitumumabpaclitaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2010-018898-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018898-37.